GLP-1 Weight Loss Projector
See what the clinical-trial average would mean for your starting weight — projected trajectory and milestones on semaglutide or tirzepatide, based on the STEP and SURMOUNT trials.
Semaglutide (Wegovy, Ozempic) — trial average: 14.9% body weight lost over 68 weeks in the STEP 1 trial (2.4mg weekly, 68 weeks).
Expected Results — Frequently Asked Questions
How much weight do people actually lose on semaglutide vs tirzepatide?
▾
In the pivotal trials, semaglutide 2.4mg averaged 14.9% of body weight lost over 68 weeks (STEP 1), and tirzepatide 15mg averaged 20.9% over 72 weeks (SURMOUNT-1). Those are averages across thousands of participants — individual results range from little response to well above average.
How fast does the weight come off?
▾
Loss is front-loaded but not instant: doses escalate over the first 16–20 weeks, appetite suppression starts within weeks, and roughly half of total trial-average loss arrives by about month five. The curve flattens as you approach a plateau near the end of the first year.
Will I keep the weight off after stopping?
▾
Trial extensions show most patients regain a substantial portion of lost weight within a year of stopping, because the medication suppresses appetite only while active. Sustainable habits built during treatment — and a maintenance plan discussed with your clinician — matter as much as the medication itself.
Medical disclaimer: This projection applies published clinical-trial averages (STEP 1 for semaglutide 2.4mg; SURMOUNT-1 for tirzepatide 15mg) to your starting weight for educational purposes. It is not a prediction of your individual results, which depend on dose, adherence, genetics, diet, and activity — and it is not medical advice. Talk to a licensed clinician about whether GLP-1 treatment is appropriate for you.